EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH (EEJPH)

ISSN: 2992-4081 ©EEJPH Publications

Volume 7 Issue 1 2025

Role of T Regulatory Cells in Modulating Adaptive Immunity

Omutindo Nyakayo A.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

T regulatory (Treg) cells are central to immune homeostasis, functioning to suppress excessive immune responses and maintain tolerance by modulating adaptive immunity. As specialized CD4+ T cell subsets identified by the transcription factor FoxP3, Tregs actively prevent autoimmunity and chronic inflammation through their interactions with T cells, B cells, and antigen-presenting cells (APCs). They employ a variety of suppressive mechanisms, including the release of immunosuppressive cytokines (e.g., IL-10, TGF-β), direct cell-to-cell contact, and metabolic regulation, each tailored to the immune context. Tregs are primarily divided into two types: thymus-derived natural Tregs (nTregs), which maintain central tolerance, and induced Tregs (iTregs), which develop in peripheral tissues and adapt to environmental antigens. In chronic infections, cancer, and autoimmune diseases, Tregs either mitigate damaging immune responses or, conversely, suppress beneficial responses, aiding immune evasion by pathogens or tumors. This review examines the origins, phenotypic markers, and mechanisms of Treg-mediated immune suppression and their complex roles in modulating adaptive immunity. We further discuss therapeutic strategies for either boosting Treg activity in autoimmune diseases or limiting Treg-mediated suppression in cancer, highlighting the potential for Treg-targeted therapies to restore immune balance and provide effective treatment for immune-mediated diseases.

Keywords: T regulatory cells, adaptive immunity, immune tolerance, FoxP3, immune modulation, cytokines

INTRODUCTION

Adaptive immunity, driven by antigen-specific responses from T and B cells, plays a crucial role in pathogen elimination and long-term immune memory [1]. However, unchecked adaptive responses can lead to autoimmunity or chronic inflammation, underscoring the need for regulatory mechanisms [2]. T regulatory (Treg) cells, a specialized subset of CD4+ T cells, are essential modulators of immune tolerance, suppressing overactive immune responses and maintaining tissue homeostasis. Identified by the expression of the transcription factor forkhead box P3 (FoxP3), Tregs operate by inhibiting effector T cells (Teffs), antigen-presenting cells (APCs), and other immune cells through direct cell contact, secretion of immunosuppressive cytokines, and modulation of metabolic pathways [3].

Tregs can be classified into two main groups: thymus-derived natural Tregs (nTregs) and peripherally induced Tregs (iTregs). While nTregs are produced in the thymus and are essential for central tolerance, iTregs arise in the peripheral tissues in response to antigens, particularly in mucosal environments, where they promote immune tolerance to self-antigens and commensal microbes [4]. The interplay between Tregs and adaptive immune cells is complex, with Tregs dynamically responding to inflammatory signals and environmental cues. This adaptability enables them to tailor their suppressive functions based on the immune context, ensuring a balanced immune response. The importance of Tregs extends beyond immune tolerance; they also shape immune responses during infections, cancer, and autoimmunity. This review provides an overview of Treg biology, exploring their differentiation, mechanisms of suppression, and role in modulating adaptive immunity, and highlights therapeutic potential for managing immune-mediated disorders.

T Regulatory Cell Biology and Development**

Origin and Types of T Regulatory Cells

T regulatory cells (Tregs) are primarily classified into two categories: natural Tregs (nTregs) and induced Tregs (iTregs).

nTregs: These cells develop in the thymus, where they are selected based on high-affinity interactions with self-antigens. This selection process is crucial for establishing central tolerance and preventing autoimmunity. The expression of the transcription factor FoxP3 is essential for the development and functional capabilities of nTregs [4, 5].

iTregs: Induced Tregs, also known as peripheral Tregs, originate from naive CD4+ T cells in peripheral tissues [6]. Their differentiation is driven by specific cytokines, particularly transforming growth factor-beta (TGF-β) and interleukin-2 (IL-2). These signals promote FoxP3 expression, enabling iTregs to assume their suppressive roles in the immune system [7].

Phenotypic Markers and Function

Tregs are characterized by high expression levels of CD25 (the IL-2 receptor alpha chain) and FoxP3, both of which are critical for their suppressive functions. Additional markers such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), glucocorticoid-induced tumor necrosis factor receptor (GITR), and CD127 (the IL-7 receptor) help differentiate Tregs from other T cell subsets [8]. Functionally, Tregs modulate immune responses through various mechanisms, including the suppression of effector T cells (Teffs), inhibition of antibody production in B cells, and regulation of antigen-presenting cell (APC) activity, thereby ensuring that immune responses remain balanced and appropriately regulated [9].

Mechanisms of Treg-Mediated Immunosuppression

Cytokine Secretion

T regulatory cells (Tregs) secrete key cytokines such as interleukin-10 (IL-10), transforming growth factor-beta (TGF-β), and IL-35, which collectively inhibit the proliferation, differentiation, and cytokine production of effector T cells (Teffs) [10]. IL-10 and TGF-β are particularly important in inducing tolerogenic phenotypes in antigen-presenting cells (APCs), thereby reducing their ability to present antigens and stimulate T cell responses [11].

Cell-to-Cell Contact

Tregs also employ direct cell-to-cell interactions to exert their suppressive effects. Through molecules like cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), Tregs engage with CD80/CD86 on APCs, inhibiting the co-stimulatory signals essential for T cell activation [12]. This interaction not only dampens T cell responses but also promotes the production of immunosuppressive enzymes such as indoleamine 2,3-dioxygenase (IDO) by APCs, further inhibiting T cell activation.

Metabolic Disruption

Additionally, Tregs actively consume high levels of IL-2, a crucial growth factor for T cell proliferation, thereby depriving Teffs of this vital resource and limiting their expansion [13]. Tregs can induce apoptosis in Teffs via granzyme and perforin release, thus contributing to the maintenance of immune homeostasis and equilibrium within the immune system [14].

Role of T Regulatory Cells in Adaptive Immunity

T regulatory cells (Tregs) play a crucial role in shaping adaptive immunity by modulating responses to pathogens, autoantigens, and tumor antigens [15]. Their function is particularly vital in maintaining immune tolerance and preventing immune-mediated diseases.

Inhibition of Effector T Cells

Tregs are instrumental in controlling the expansion and activity of both CD4+ and CD8+ effector T cells (Teffs). By limiting cytokine production and reducing Teff proliferation, Tregs help prevent excessive tissue damage during infections and autoimmune responses [16]. Furthermore, Tregs facilitate immune memory by allowing for controlled Teff activation, ensuring that responses are effective without causing extensive tissue injury [17].

Modulation of B Cell Responses

In addition to their effects on T cells, Tregs influence B cell activity by inhibiting antibody production and promoting the development of tolerogenic B cells [18]. They achieve this through direct interactions and the secretion of inhibitory cytokines, leading to reduced antibody-mediated autoimmunity and a more regulated humoral response.

Regulation of APC Function

Tregs also condition antigen-presenting cells (APCs) to present antigens in a non-inflammatory context, thereby preventing the activation of naive T cells toward an immune-reactive state [19]. This regulatory interaction is

particularly critical in tissues where self-tolerance must be maintained, such as in the gut, skin, and lungs, thereby ensuring a balanced immune response that protects against harmful overreactions.

T Regulatory Cells in Disease Contexts

Autoimmunity

Dysfunction or a reduced number of T regulatory cells (Tregs) has been linked to various autoimmune diseases, including rheumatoid arthritis, type 1 diabetes, and multiple sclerosis [20]. In these conditions, impaired Treg function results in unchecked activity of effector T cells (Teffs), which promotes self-reactivity and chronic inflammation.

Chronic Infections

In the context of chronic infections such as HIV and hepatitis, Tregs play a dual role. While they help control inflammation, they may also contribute to pathogen persistence by suppressing effective immune responses [21]. This creates a delicate balance between managing inflammation and promoting pathogen clearance, which can vary significantly depending on the specific infection.

Cancer

In the tumor microenvironment, Tregs can inhibit anti-tumor immune responses, allowing cancer cells to evade immune surveillance [22]. Elevated levels of Tregs in tumors correlate with poor patient outcomes, as these cells can dampen the activity of effector T cells critical for tumor elimination [23]. Consequently, strategies targeting Tregs in cancer therapy aim to enhance effector T cell function while carefully managing the risk of autoimmune side effects, thereby improving the overall efficacy of cancer immunotherapies [24].

Therapeutic Targeting of Tregs

Therapeutic strategies focusing on T regulatory cells (Tregs) vary based on the disease context. In autoimmune diseases, enhancing Treg function is beneficial. For instance, low-dose IL-2 therapy aims to expand Treg populations, thereby restoring immune tolerance and reducing autoimmunity [25]. Conversely, in cancer, the goal often shifts to inhibiting Treg activity. Checkpoint inhibitors targeting pathways like CTLA-4 and PD-1 are employed to reduce Treg-mediated suppression of effector T cells (Teffs) [26]. This approach enhances the anti-tumor immune response, allowing for more effective targeting of cancer cells. These therapeutic interventions highlight the importance of context-specific strategies in modulating Treg function, balancing immune regulation to either restore tolerance in autoimmune conditions or boost anti-tumor immunity in cancer. By fine-tuning Treg activity, there is potential for more effective treatment outcomes across various disease states.

CONCLUSION

T regulatory cells are indispensable in modulating adaptive immunity, balancing immune tolerance with effective pathogen defense. By suppressing excessive immune activation and promoting tolerance, Tregs maintain immune homeostasis, protecting against autoimmunity while influencing responses to chronic infections and cancer. Understanding the dynamics of Treg function in different immunological contexts opens new avenues for therapeutic interventions aimed at restoring immune balance.

REFERENCES

1. Gardiner CM, Mills KH. The cells that mediate innate immune memory and their functional significance in inflammatory and infectious diseases. SeminImmunol. 2016 Aug;28(4):343-50. doi: 10.1016/j.smim.2016.03.001. Epub 2016 Mar 12. PMID: 26979658.
2. Afonina IS, Zhong Z, Karin M, Beyaert R. Limiting inflammation-the negative regulation of NF-κB and the NLRP3 inflammasome. Nat Immunol. 2017 Jul 19;18(8):861-869. doi: 10.1038/ni.3772. PMID: 28722711.
3. Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol. 2012 Mar 21;3:51. doi: 10.3389/fimmu.2012.00051. PMID: 22566933; PMCID: PMC3341960.
4. Elkord E. Thymus-Derived, Peripherally Derived, and in vitro-Induced T Regulatory Cells. Front Immunol. 2014 Jan 24;5:17. doi: 10.3389/fimmu.2014.00017. PMID: 24478778; PMCID: PMC3900873.
5. Stritesky GL, Jameson SC, Hogquist KA. Selection of self-reactive T cells in the thymus. Annu Rev Immunol. 2012;30:95-114. doi: 10.1146/annurev-immunol-020711-075035. Epub 2011 Dec 5. PMID: 22149933; PMCID: PMC3518413.
6. Schmidt A, Éliás S, Joshi RN, Tegnér J. In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol. J Vis Exp. 2016 Dec 30;(118):55015. doi: 10.3791/55015. PMID: 28060341; PMCID: PMC5226637.
7. Lu L, Zhou X, Wang J, Zheng SG, Horwitz DA. Characterization of protective human CD4CD25 FOXP3 regulatory T cells generated with IL-2, TGF-β and retinoic acid. PLoS One. 2010 Dec 17;5(12):e15150. doi: 10.1371/journal.pone.0015150. PMID: 21179414; PMCID: PMC3003689.

8. Gonçalves-Lopes RM, Lima NF, Carvalho KI, Scopel KK, Kallás EG, Ferreira MU. Surface expression of inhibitory (CTLA-4) and stimulatory (OX40) receptors by CD4+ regulatory T cell subsets circulating in human malaria. Microbes Infect. 2016 Oct;18(10):639-648. doi: 10.1016/j.micinf.2016.06.003. Epub 2016 Jun 16. PMID: 27320393; PMCID: PMC5087799.
9. Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol. 2012 Mar 21;3:51. doi: 10.3389/fimmu.2012.00051. PMID: 22566933; PMCID: PMC3341960.
10. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT, Brüning JC, Müller W, Rudensky AY. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. 2011 Apr 22;34(4):566-78. doi: 10.1016/j.immuni.2011.03.018. PMID: 21511185; PMCID: PMC3088485.
11. Torres-Aguilar H, Aguilar-Ruiz SR, González-Pérez G, Munguía R, Bajaña S, Meraz-Ríos MA, Sánchez-Torres C. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T cells. J Immunol. 2010 Feb 15;184(4):1765-75. doi: 10.4049/jimmunol.0902133. Epub 2010 Jan 18. PMID: 20083662.
12. Tekguc M, Wing JB, Osaki M, Long J, Sakaguchi S. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc Natl AcadSci U S A. 2021 Jul 27;118(30):e2023739118. doi: 10.1073/pnas.2023739118. PMID: 34301886; PMCID: PMC8325248.
13. Rosenzwajg M, Churlaud G, Mallone R, Six A, Dérian N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, Pham HP, Hartemann A, Yu A, Pugliese A, Malek TR, Klatzmann D. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun. 2015 Apr;58:48-58. doi: 10.1016/j.jaut.2015.01.001. Epub 2015 Jan 26. PMID: 25634360; PMCID: PMC8153751.
14. Koristka S, Cartellieri M, Arndt C, Feldmann A, Töpfer K, Michalk I, Temme A, Ehninger G, Bachmann M. Cytotoxic response of human regulatory T cells upon T-cell receptor-mediated activation: a matter of purity. Blood Cancer J. 2014 Apr 11;4(4):e199. doi: 10.1038/bcj.2014.20. PMID: 24727995; PMCID: PMC4003414.
15. Goswami TK, Singh M, Dhawan M, Mitra S, Emran TB, Rabaan AA, Mutair AA, Alawi ZA, Alhumaid S, Dhama K. Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders - Advances and challenges. Hum VaccinImmunother. 2022 Dec 31;18(1):2035117. doi: 10.1080/21645515.2022.2035117. Epub 2022 Mar 3. PMID: 35240914; PMCID: PMC9009914.
16. Bluestone JA, McKenzie BS, Beilke J, Ramsdell F. Opportunities for Treg cell therapy for the treatment of human disease. Front Immunol. 2023 Apr 19;14:1166135. doi: 10.3389/fimmu.2023.1166135. PMID: 37153574; PMCID: PMC10154599.
17. Hu G, Liu Z, Zheng C, Zheng SG. Antigen-non-specific regulation centered on CD25+Foxp3+ Treg cells. Cell MolImmunol. 2010 Nov;7(6):414-8. doi: 10.1038/cmi.2010.39. Epub 2010 Aug 23. PMID: 20729905; PMCID: PMC3094156.
18. Boonpiyathad T, Sözener ZC, Akdis M, Akdis CA. The role of Treg cell subsets in allergic disease. Asian Pac J Allergy Immunol. 2020 Sep;38(3):139-149. doi: 10.12932/AP-030220-0754. PMID: 32563231.
19. André S, Tough DF, Lacroix-Desmazes S, Kaveri SV, Bayry J. Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol. 2009 May;174(5):1575-87. doi: 10.2353/ajpath.2009.080987. Epub 2009 Apr 6. PMID: 19349365; PMCID: PMC2671245.
20. Scheinecker C, Göschl L, Bonelli M. Treg cells in health and autoimmune diseases: New insights from single cell analysis. J Autoimmun. 2020 Jun;110:102376. doi: 10.1016/j.jaut.2019.102376. Epub 2019 Dec 18. PMID: 31862128.
21. Chevalier MF, Weiss L. The split personality of regulatory T cells in HIV infection. Blood. 2013 Jan 3;121(1):29-37. doi: 10.1182/blood-2012-07-409755. Epub 2012 Oct 4. PMID: 23043072.
22. Paluskievicz CM, Cao X, Abdi R, Zheng P, Liu Y, Bromberg JS. T Regulatory Cells and Priming the Suppressive Tumor Microenvironment. Front Immunol. 2019 Oct 15;10:2453. doi: 10.3389/fimmu.2019.02453. PMID: 31681327; PMCID: PMC6803384.
23. Shou J, Zhang Z, Lai Y, Chen Z, Huang J. Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis. BMC Cancer. 2016 Aug 26;16(1):687. doi: 10.1186/s12885-016-2732-0. PMID: 27566250; PMCID: PMC5002190.
24. Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017 Jan;27(1):109-118. doi: 10.1038/cr.2016.151. Epub 2016 Dec 20. PMID: 27995907; PMCID: PMC5223231.

25. Graßhoff H, Comdühr S, Monne LR, Müller A, Lamprecht P, Riemekasten G, Humrich JY. Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases. Front Immunol. 2021 Apr 1;12:648408. doi: 10.3389/fimmu.2021.648408. PMID: 33868284; PMCID: PMC8047324.
26. Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017 May;47(5):765-779. doi: 10.1002/eji.201646875. Epub 2017 Apr 24. PMID: 28393361.

CITE AS: Omutindo Nyakayo A. (2025). Role of T Regulatory Cells in Modulating Adaptive Immunity. EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH, 7(1):7-11